Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | DRD4 | P21917 | 3/20 | 0.45 |
| ▸ | DRD3 | P35462 | 3/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 9/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17407617 | 0.88 | DRD2 (0.43) | DRD2DRD4DRD3RIPK1CCNE1 | |
| SCHEMBL4734771 | 0.87 | DRD2 (0.47) | DRD2DRD4DRD3RIPK1CCNE1 | |
| SCHEMBL19646802 | 0.85 | DRD2 (0.43) | DRD2DRD4DRD3RIPK1CCNE1 | |
| SCHEMBL29587840 | 0.79 | DAO (0.44) | DRD2DRD4DRD3RIPK1CCNE1 | |
| SCHEMBL2176426 | 0.78 | LOXL2 (0.52) | DRD2DRD4DRD3RIPK1CCNE1 | |
| SCHEMBL1939638 | 0.78 | DRD2 (0.50) | DRD2DRD4DRD3RIPK1CCNE1 | |
| SCHEMBL27748121 | 0.77 | DAO (0.40) | DRD2DRD4DRD3RIPK1CCNE1 | |
| SCHEMBL26686565 | 0.76 | GCK (0.43) | DRD2DRD4DRD3 | |
| SCHEMBL8135643 | 0.76 | RIPK1 (0.47) | RIPK1DAOCCNB2CDK1CCNB1 | |
| SCHEMBL7411386 | 0.76 | DRD2 (0.49) | DRD2DRD4DRD3RIPK1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828345-B2 | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160002172-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002172-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | ROCK1, ROCK2, MYLK | DRD2 4035/4885DRD4 4425/4885DRD3 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.